-
Pre-Open Stock Movers 07/25: (GNVC) (OUTR) (S) Higher; (SC) (WAB) (ROP) Lower (more...)
-
BIND Therapeutics (BIND) Announces Receipt of Two Competing Bids (PFE)
-
BIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets
-
Pfizer's (PFE) 'Stalking Horse Bid' Leaves Little Room for BIND Therapeutics' (BIND) Holders -Stifel
-
BIND Therapeutics (BIND) Files Bankruptcy Court Motion Following Stalking Horse Bid from Pfizer
-
BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.
-
BIND Therapeutics (BIND) Announces Resignation of Polaris-Affiliated Directors
-
BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners
-
BIND Therapeutics (BIND) Provides Update on Chapter 11 Proceedings, Enters Agreement with Hercules Technology III, L.P.
-
BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.
-
Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS® to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and
-
BIND Therapeutics (BIND) Misses Q1 EPS by 6c
-
BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
-
Hercules Announces First Quarter 2016 Financial Results and Quarterly Dividend of $0.31 per Share
-
BIND Therapeutics (BIND) Enters Research Collaboration with Affilogic; Will Utilize Nanofitins
-
BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor Immunity
-
Stifel Downgrades BIND Therapeutics (BIND) to Hold Following Chapter 11
-
Unusual 11 Mid-Day Movers 5/2: (OPWR) GNW) (SRPT) Higher; (BIND) (PRGN) (GLBS) Lower
-
Pre-Open Stock Movers 05/02: (PTX) (OPWR) (OREX) (APOL) Higher; (NRX) (BIND) (UPL) (BIDU) Lower (more...)
-
BIND Therapeutics (BIND) Files Chapter 11 Bankruptcy
-
BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding
-
BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Pla

